Skip to content

Current ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.5×+0.1×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
3.6×-1.4×
AbbVie logo
AbbVieABBV
0.8×0.0×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
7.7×-14.9×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×
Arcus Biosciences logo
Arcus BiosciencesRCUS
-1.3×

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.1B+259%
Enterprise value$1.06B+251%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0.0×

Where this comes from

Calculated from Corvus Pharmaceuticals’s reported figures.

Based on the most recent quarter.

The official record: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corvus Pharmaceuticals's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corvus Pharmaceuticals's current ratio?
Corvus Pharmaceuticals (CRVS) reported current ratio of 19.8× in Q1 2026.
How has Corvus Pharmaceuticals's current ratio changed year-over-year?
Corvus Pharmaceuticals's current ratio increased by 304.2% year-over-year, from 4.9× to 19.8×.
What is the long-term trend for Corvus Pharmaceuticals's current ratio?
Over 5 years (2020 to 2025), Corvus Pharmaceuticals's current ratio has grown at a 10.7% compound annual growth rate (CAGR), from 3.7× to 6.2×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.